Key takeaways:Amgen is enrolling participants in two phase 3 studies, MARITIME-OSA-1 and MARITIME-OSA-2, for its investigational drug MariTide. The studies are currently recruiting participants aged 18 or older who have moderate to severe obstructive sleep apnea (OSA) and a body mass index (BMI) of 27 kg/m2 or more. The OSA-specific pipeline programs include:MARITIME-OSA-1, a phase 3 study of MariTide, is enrolling adults living with obstructive sleep apnea on positive airway pressure therapy and living with obesity or overweight. MARITIME-OSA-2, a Phase 3 study of MariTide, is enrolling adults living with obstructive sleep apnea not on positive airway pressure therapy and living with obesity or overweight. More in Sleep Apnea & Obesity:Photo: Amgen scientists look at data in drug product and device development.